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Point-of-care testing comes of age in Australia
Mark Shephard, Associate Professor, Director and Senior Research Fellow, Community 
Point-of-Care Services, Flinders University Rural Clinical School, Adelaide 
Summary
A wide range of point-of-care tests is available and 
being used in both hospital and community settings 
for acute and chronic illnesses. There have been 
significant improvements in device technology as 
well as advances in training methods, procedures to 
monitor analytical quality, and the electronic capture 
and management of test results from a central 
location. Various point-of-care tests have been found 
to be non-inferior to laboratory testing for managing 
chronic conditions in general practice and Aboriginal 
medical services. Maintaining the analytical quality 
of devices and ensuring that staff are properly 
trained are critical elements in sustaining a high 
quality point-of-care testing service. 
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introduction
Point-of-care testing can be defined as pathology testing 
performed on-site during the patient consultation. It allows 
a rapid test result to be generated and used to make an 
immediate, informed clinical decision. 
There have been significant technological and analytical 
advances in point-of-care testing devices and reagent 
manufacture. An increasing range of tests can now be performed 
on very small sample volumes in less than 10 minutes. These 
include tests for glucose, glycated haemoglobin (HbA1c), lipids, 
electrolytes, urea and creatinine, blood gases and coagulation 
and cardiac markers. The analytical performance of many 
point-of-care testing devices is equivalent to that of a laboratory 
and meets profession-derived analytical goals.1,2
Clinical applications
Point-of-care tests (both singly and in profile) are now available 
for acute and chronic situations and can be used for example 
in managing diabetes, warfarin requirements, electrolyte and 
acid–base disturbances and risk stratification of patients with 
suspected acute coronary syndrome. Table 1 lists examples of 
the more common biochemistry and haematological tests. Some 
tests such as haemoglobin and INR have both chronic and acute 
applications.
     Abnormal laboratory results 
Table 1
Point-of-care tests for chronic and acute care 
Parameters Test 
Chronic care
Carbohydrate  
   metabolism
Glucose  
Glycated haemoglobin
Lipids Triglyceride 
Total cholesterol  
High-density lipoprotein cholesterol 
Low-density lipoprotein cholesterol 
   (calculated)
Renal function Urea  
Creatinine (estimated glomerular 
   filtration rate)  
Urine albumin 
Urine albumin–creatinine ratio
Haematological/ 
coagulation
Haemoglobin 
INR
Liver function Total protein  
Albumin 
Alanine aminotransferase 
Aspartate aminotransferase 
Gamma-glutamyltranspeptidase
Alkaline phosphatase 
Bilirubin
Acute care
electrolytes Sodium  
Potassium 
Chloride 
Total Co2
Anion gap
Arterial blood gas pH  
Partial pressure Co2
Partial pressure o2
Saturated o2
Base excess
Cardiac function Troponin I  
Troponin T 
Creatine kinase myocardial band 
Myoglobin 
N-terminal pro b-type natriuretic peptide
Brain natriuretic peptide
Miscellaneous
C-reactive protein 
Ionised calcium
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Models of community-based point-of-care testing
The national Quality Assurance for Aboriginal and Torres  
Strait Islander Medical Services (QAAMS) Program  
(www.qaams.org.au) provides glycated haemoglobin (HbA1c) 
and urine albumin–creatinine ratio testing for diabetes 
management in over 100 indigenous medical services 
across Australia.2,5 
Queensland Health's statewide i-STAT network provides 
portable analysers throughout Queensland. These measure 
blood gases, electrolytes, coagulation, haematological and 
cardiac markers in critical care situations.6 
The Integrated Cardiovascular Clinical Network SA (iCCnet 
SA) operates in rural South Australia (www.iccnetsa.org.au).
Glycaemic control
HbA1c remains the gold standard pathology test for long-term 
monitoring of glycaemic control in patients with diabetes. Devices 
measure HbA1c using either immunoassay or boronate affinity 
chromatography methods.
There are numerous strip-based testing devices for glucose 
monitoring. These generally measure whole blood glucose  
rather than plasma glucose, although newer devices can report  
a plasma-equivalent glucose concentration.
Blood lipids
Measuring blood lipids is useful for cardiovascular disease risk 
assessment and for managing patients on lipid lowering therapy. 
Testing devices measure a full lipid profile on capillary or venous 
blood. However, they calculate the low density lipoprotein (LDL) 
cholesterol using the Friedewald formula and cannot, as yet, 
determine LDL cholesterol directly as laboratories can now do.
Assessing renal function
Quantitative measurement of urine albumin or urine albumin–
creatinine ratio is a key component in the review of patients with 
diabetes. Plasma creatinine measurement is currently the subject 
of an international standardisation, in which both laboratory and 
point-of-care testing methods are being aligned to an isotope 
dilution mass spectrometry reference method. 
Warfarin monitoring
Point-of-care INR testing is becoming increasingly popular in 
general practice for monitoring patients on warfarin therapy.3 
Results can be linked with computer decision support software that 
automatically recommends the patient's next dose of warfarin. 
Acute care
In an acute situation, electrolytes (including anion gap), blood 
gases and cardiac markers, notably troponin I or T, can be 
assessed. Some devices can measure these cardiac troponins 
down to the nanogram per mL range. Newer markers including 
brain natriuretic peptide (BNP) and N-terminal pro b-type 
natriuretic peptide (NT-proBNP) remain expensive and their 
clinical utility continues to be debated. 
Point-of-care testing models 
In Australia, point-of-care testing is being used in the community 
as well as in hospitals particularly in rural and remote areas where 
access to laboratory services may be poor. There are now a number 
of working examples of innovative community-based point-of-care 
testing models that have improved clinical outcomes in both chronic 
and acute situations and are analytically sound (see box). 
Managing point-of-care testing
A systematic approach is needed to organise and manage a 
sustainable and clinically effective point-of-care testing service.4
Physical requirements
only a small area of dedicated bench space is required to conduct 
most point-of-care testing, as most devices are 'desktop' in size 
or smaller. Most devices require an AC power source although an 
increasing number of newer devices can work off battery power 
as well. Storage of reagents and consumables is generally at 
room temperature or 4o C, depending on the individual test.
Staff training
Training programs for staff who perform the tests (such as 
doctors, nurses and Aboriginal health workers) are required. The 
type and duration of training needed depends on the complexity 
of the device and the range of tests available, as well as the 
number of people being trained. For example, a training session 
for a simple device such as a glucose meter for a small number 
of trainees may take less than half a day, while regional training 
workshops for the Quality Assurance for Aboriginal and Torres 
Strait Islander Medical Services (QAAMS) Program, the largest 
national point-of-care testing program for diabetes management, 
take two full days for 20–30 trainees. Initial and ongoing training 
with competency assessment and updates are crucial for a 
sustainable high quality point-of-care testing service. Web-based 
training is now available for some Australian models.2,5 
Analytical quality
A management system incorporating quality control and quality 
assurance processes adapted for non-laboratory settings is needed 
to continually ensure that the analytical quality of point-of-care 
testing results is appropriate for patient care. 
The frequency of these checks depends on a number of factors 
including device complexity, size of the point-of-care network 
and the volume of patient testing at each site. For example, in 
the QAAMS program for diabetes management, quality control 
and quality assurance testing is performed monthly.2 Should an 
abnormal result be obtained that does not fit the patient's clinical 
picture, the treating practitioner should repeat the point-of-care test 
and send the sample to the laboratory for confirmation of the result. 
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laboratory or specialist point-of-care testing service provider to 
support and maintain their service. These services may be helpful 
when selecting a device and with training and quality surveillance. 
The capacity to sustain a point-of-care testing service in a remote 
health service setting is often limited by high rates of staff (device 
operator) turnover.13 
At present there is no Medicare rebate for point-of-care tests in 
general practice (other than a small group of mainly qualitative 
tests such as a pregnancy test). This limits the potential uptake 
of point-of-care technology and means a thorough cost–benefit 
analysis is needed before making the decision to implement 
point-of-care testing.
Conclusion 
General practice and particularly rural and remote medical 
services are increasingly using point-of-care testing. 
Technological advances in device and reagent manufacture 
have now ensured that this type of pathology testing can be 
performed safely and effectively. It is convenient and accessible 
for the patient and allows immediate decision making for the 
doctor. Nonetheless, in implementing point-of-care testing, 
a significant commitment to operator training (particularly 
in the face of high staff turnover rates in remote areas) and 
surveillance of analytical quality are paramount.
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To sustain a point-of-care testing service, it is important to have 
ongoing technical support from the manufacturer of the device.
Test results
A further recent technological advance has been the capacity 
to send results electronically from multiple point-of-care 
testing devices to a central management point and from there 
to a clinical or hospital information system. This improved 
connectivity has enhanced the ability to develop large-scale 
point-of-care testing networks and streamline the delivery of 
testing services. Many Australian diagnostic companies provide 
connectivity software for their testing devices.
is point-of-care testing effective?
There is a growing evidence base for the clinical, operational and 
economic effectiveness of point-of-care testing in hospitals and in 
the community. 
Chronic care
For chronic care, there are published examples of how point-of- 
care testing can be an effective tool for improving control of 
chronic conditions either by reductions in HbA1c (for diabetes 
management)7 or increased time in therapeutic or target ranges 
(coagulation studies).3 
Acute care
The ability to perform tests such as potassium and blood gases by 
point-of-care testing in under five minutes on an acutely ill patient 
can inform initial management. For example, being able to measure 
potassium levels in a patient presenting with severe vomiting or 
diabetic ketoacidosis in a remote health centre is particularly useful. 
Similarly, the ability to rapidly stratify risk in patients with suspected 
acute coronary syndrome using supportive cardiac marker point-
of-care testing can have benefits. These relate to reduced length of 
stay in emergency departments or reduced mortality through more 
rapid and effective risk stratification and treatment.8,9
General practice
A large randomised controlled trial of point-of-care testing in 
Australian general practice was commissioned by the Department 
of Health and Ageing.10 As part of the trial, the effectiveness 
of point-of-care testing versus laboratory testing was assessed 
for managing chronic conditions in general practice. Data 
from 53 practices located in urban, rural and remote locations 
in Australia were analysed. Based on the primary outcome 
of percentage of patients with test results in the target range, 
point-of-care tests for HbA1c, urine albumin, albumin–creatinine 
ratio, total cholesterol and triglycerides were non-inferior to 
laboratory testing, but not for INR and HDL cholesterol.11,12
Limitations of point-of-care testing 
While point-of-care testing may appear simple and easy to adopt, 
it is critical that health professionals seek the support of their local 
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The Australian Adverse Drug Reactions Bulletin was first 
published in 1974.1 This monthly publication became colloquially 
known as the ADRAC Bulletin as its content was determined by 
the Adverse Drug Reactions Advisory Committee.
In 1975 Australian Prescriber was launched and the ADRAC 
Bulletin was incorporated into it. There was some initial disquiet 
about the merger as the rate of reporting of adverse drug reactions 
reduced. This fall may have reflected the change from monthly to 
quarterly publication of the Bulletin.2
The Adverse Drug Reactions section was a regular feature of 
Australian Prescriber until 1982, when the publication of the 
journal was temporarily suspended.3 The Bulletin then resumed its 
existence as a separate publication. It remained separate when the 
publication of Australian Prescriber restarted in 1983. 
Both publications were distributed using a government mailing 
list, but an Australian Prescriber survey in 1989 found that more 
than 25% of respondents were not receiving the publications.4 This 
problem was mentioned in the Baume review of drug evaluation 
in 1991. The review recommended that the mailing list should 
contain at least all medical practitioners, pharmacists and dentists. 
This was because the Bulletin was recognised as the major means 
of informing health professionals about the analysis of adverse 
drug reaction reports.5
Shortly after the Baume review a decision was made to distribute 
the Bulletin in the same package as Australian Prescriber. Although 
there were concerns that this could affect the rate of reporting of 
adverse reactions, the joint mailing went ahead. This arrangement 
has continued until now, despite Australian Prescriber moving 
publishers.3 In 1999 Australian Prescriber increased publication to 
six issues per year and the Bulletin followed in 2003.
From 2010, information about adverse reactions will once again 
be included in a special section of Australian Prescriber. Medicines 
Safety Update will be prepared by the production team of the 
former ADRAC Bulletin under the guidance of the new office of 
Medicines Safety Monitoring (oMSM). As the electronic version 
of Australian Prescriber has many overseas readers, the new 
arrangements will deliver important information about adverse 
reactions to a wider audience.
Australian Prescriber is pleased to be part of the new direction 
for informing health professionals about adverse reactions to 
medicines. 
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